Search PubMed⌕ Search

Biomedical subjects

D Brackertz

Publications and source records attributed to D Brackertz.

44 records · Page 3Linked to original sources
PubMedDate not supplied

Comparison of clofezone and diclofenac in the treatment of out-patients suffering from activated (painful) osteoarthrosis.

The effectiveness and acceptability of clofezone (Perclusone) were compared with those of diclofenac in a placebo-controlled, double-blind, cross-over trial on a group of 29 out-patients suffering from osteoarthrosis of the knee or hip. Clofezone was given at a daily dosage of 1200 mg during the first week and 600 mg during the second week; the corresponding dosages of diclofenac were 150 mg and 75 mg. The duration of the trial was 6 weeks. In order to wash out previous medication, a placebo was given for one week before and after each medication period. Eight of the patients stopped taking their drug after 1--3 weeks, namely 5 in the clofezone group and 3 in the diclofenac group, while one patient stopped taking the placebo. The principal reason for these stoppages was gastrointestinal intolerance. These 9 patients were disregarded in the evaluation of the trial results. This evaluation on the remaining 20 patients showed that clofezone brought about a significant improvement in respect of pain (both at rest and during movement), inflammation and mobility after two weeks' application. In the diclofenac group the only significant improvement after the same period was in respect of pain during movement. Statistical comparison of the two groups showed that the reduction in pain during movement and in inflammation was significantly greater under clofezone than under diclofenac and that clofezone had the longer-lasting action. These findings are discussed in the light of the kinetic characteristics of the two drugs and of the mild antidepressant properties of clofezone. There was no significant difference between the two drugs as regards tolerance.

Adult↗
PubMedDate not supplied

[Genetic influences in chronic polyarthritis].

Genetically determined diseases exhibit the following characteristics: 1. They appear with different frequencies in various populations. 2. They show tendencies to aggregate in certain families. 3. The disease risk is higher for monozygotic twins than for dizygotic twins. 4. They show an association with genetically determined markers in a population e.g. certain HLA-antigens. All of these characteristics are observed in rheumatoid arthritis. Despite an abundance of data suggesting a genetic influence in the etiopathogenesis of rheumatoid arthritis, it has not been possible, as yet, to uncover a definitive genetic mechanism. There is evidence to suggest that both histocompatibility-complex-associated genetic factors and genes outside the HLA region are of significance for predisposition to the disease and possible for the pathogenesis and course of rheumatoid arthritis. Using modern genetic technology it should be possible to investigate further the influence of genetic factors on the etiology and pathogenesis of rheumatoid arthritis.

Arthritis, Rheumatoid↗
PubMedDate not supplied

[Chlorambucil pulse therapy in progressive chronic polyarthritis. Initial results of an open multicenter study].

The first preliminary clinical results with chlorambucil pulse-therapy in patients with refractory rheumatoid arthritis are reported, with a dose of chlorambucil below that which might risk inducing leukaemia. The clinical response was good in 15 out of 19 patients; symptoms and objective findings of rheumatoid arthritis had significantly improved. However, multiple toxic reactions have been identified in our patients.

Adult↗